CN101475553A - Preparation, medicinal preparation and use of dihydromyricetrin - Google Patents
Preparation, medicinal preparation and use of dihydromyricetrin Download PDFInfo
- Publication number
- CN101475553A CN101475553A CNA2009100665184A CN200910066518A CN101475553A CN 101475553 A CN101475553 A CN 101475553A CN A2009100665184 A CNA2009100665184 A CN A2009100665184A CN 200910066518 A CN200910066518 A CN 200910066518A CN 101475553 A CN101475553 A CN 101475553A
- Authority
- CN
- China
- Prior art keywords
- dibydro myricetrin
- ampelopsis
- described method
- myricetrin
- dibydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a method for extracting dihydromyricetin from stem leaves of Ampelopsis sinica(Miq.)W.T.Wang of Ampelopsis Michx and stem leaves of Ampelopsis grossedetata(Hand- Mazz)W.T.wang, a medicine preparation and new medical application. The dihydromyricetin can be applied to prevention and treatment of senile dementia. A prepared medicine can either contain the dihydromyricetin only, or be a composition containing the dihydromyricetin, and can be pharmaceutical preparations, such as tablets, capsules, granules, and dripping pills or injections.
Description
Technical field
The invention relates to a kind of novel method, pharmaceutical preparation and new medical use thereof that from Vitaceae ampelopsis Stem or leaf of Amur Ampelopsis and Ampelopsis grossedentata, extracts preparation medicine material dibydro myricetrin, belong to medical technical field.
Background technology
Mainly contain dibydro myricetrin and ampelopsin in ampelopsis Stem or leaf of Amur Ampelopsis and the Ampelopsis grossedentata, the bibliographical information dibydro myricetrin extracts and mainly comprises by all kinds of SOLVENTS (water or organic solvent) decoction or supersound extraction vitaceae, concentrate, the reusable heat water dissolution, filtered while hot, filtrate are directly used chromatographic separation; Medicinal material is soaked in solvent, filter, carry out microwave radiation processing, merging filtrate, heating in water bath extracts, filtered while hot, filtrate is separated with the method for hot water dissolving, cold water recrystallization and is purified; Microwave extract method combines with the dynamic circulating-stage continuous countercurrent extracting method.The said extracted method is mainly complicated operation, equipment requirements is higher, is unfavorable for suitability for industrialized production.
Characteristics of the present invention are not concentrate directly upward macroporous resin column behind the extraction using alcohol, and are simple to operate, and solved the problem that concentrated back solution muddiness is unfavorable for upper prop.Whole production technology is simple, with short production cycle, and safe, free from environmental pollution, cost is low, the yield height, and dibydro myricetrin purity is particularly suitable for the industrialization mass production up to more than 95%.
The bibliographical information dibydro myricetrin has reducing blood-fat, hypoglycemic, protection kidney and hepar damnification, anti-oxidant, anti-inflammatory, cough-relieving, hypertension, effect such as antibacterial.There is not report to have the effect of prevention and treatment senile dementia.Senile dementia will be that China is to one of maximum mental disorder of health of people harm.Senile dementia mainly can be divided into cerebrovascular property senile dementia, dementia of the Alzheimer type, mixed type and other type etc.The brain cell that the elderly causes because of cerebrovascular disorder is aging, makes transmission such as thinking, the motion dementia that causes of being obstructed be called the cerebrovascular property senile dementia.Cerebral arteriosclerosis, cerebral thrombosis, Intracerebral hemorrhage and hypertension etc. cause that easily this disease, about 40% scientist think that one of main pathogenic factor of senile dementia is that infringement has taken place getting in touch on cerebro-vascular diseases and some cranial nerve maincenter and the function.Senile dementia has become one of principal disease that threatens mankind's quality of life in old age, and morbidity is ascendant trend year by year.Owing to lack effective methods of treatment, senile dementia has become the 4th human after heart trouble, cancer and the apoplexy cause of the death.Therefore, seek the active drug of treatment senile dementia, the cause of disease and the treatment of research senile dementia have crucial meaning.Become one of research focus of field of medicaments.And has good social benefit.
The dibydro myricetrin structural formula
Summary of the invention
One of purpose of the present invention provides the application of single component dibydro myricetrin in the treatment senile dementia.Dibydro myricetrin is used to prepare the new purposes of senile dementia prevention and cure specifically.Through experimentation on animals, the learning and memory function of dementia mice can be significantly improved, and the activity of SOD can be obviously improved, reduce the content of MDA, improve the brain coefficient, the safe and effective pharmaceutical preparation that can be used for preventing and treating senile dementia finally is provided.Before the present patent application, do not see the report of using prevention of dibydro myricetrin monomer component and treatment senile dementia is arranged.
Two of the object of the invention has provided the extraction and separation method of dibydro myricetrin, mostly the method for disclosed in the past extraction separation dibydro myricetrin is to decoct or the supersound extraction vitaceae by all kinds of SOLVENTS (water or organic solvent), concentrate, the reusable heat water dissolution, filtered while hot, filtrate are directly used chromatographic separation; Or medicinal material soaked in solvent, filter, carry out microwave radiation processing, merging filtrate, heating in water bath extracts, filtered while hot, filtrate is separated with the method for hot water dissolving, cold water recrystallization and is purified; Or microwave extract method combines with the dynamic circulating-stage continuous countercurrent extracting method.Be not suitable for industrialization production.The present invention has adopted gac degreasing in ethanol extract safely and effectively to remove the method for impurity such as chlorophyll.And ethanol extract directly passes through macroporous resin column, remove water-insoluble impurity, effective constituent is directly eluted by ethanol extract, solve the difficult problem that the water-insoluble sample is not easy macroporous resin column, saved ethanol, reduced cost, helping crystalline separates out, workable, be fit to industrial production, also be one of main innovation of the present invention.The present invention separates the method for dibydro myricetrin, and cost is low, and is easy to operate, the sample purity height of acquisition, and the content of dibydro myricetrin is up to more than 95%.
It also is a new technology that three of purpose of the present invention is utilized the anti-phase normal pressure column separating purification of C-18 dibydro myricetrin composition.The isolating dibydro myricetrin purity of this method height (content 98%) can be followed the specification according to needs design post owing to adopt the normal pressure separator column, can prepare the high purity dibydro myricetrin in a large number, and separator column can use repeatedly, and is easy to operate.
Four of purpose of the present invention has provided the pharmaceutical preparation of single component dibydro myricetrin, is mainly oral preparations.Said oral preparations is selected from any in tablet, capsule, pill, granule, suspensoid, dripping pill, the oral liquid.
But being medicines, five of purpose of the present invention preferably contains the pharmaceutical excipient of 1%-99% dibydro myricetrin and 99%-1% or the medicine of other prescription.Auxiliary material in the medicine is meant conventional vehicle, as solvent, disintegrating agent, correctives, sanitas, tinting material, tackiness agent etc.The medicine that other compatibility in the medicine of the present invention is used, the dibydro myricetrin that refers to effective dose is certain medicine material, again compatibility other allowed the Chinese medicine or the pharmaceutical chemicals that share.
The present invention implements by the following method: Vitaceae ampelopsis Stem or leaf of Amur Ampelopsis cauline leaf and Ampelopsis grossedentata cauline leaf extract one or many with 50-80% ethanol or methanol solution, filtered while hot, united extraction liquid, add 0.01-3% gac, filter, filtrate is crossed macroporous resin column, and effluent liquid concentrates, crystallization (4-10 ℃) gets crude extract; Crude extract must the dihydromyricetin cellulose crystal with ethanol-cold water, methyl alcohol-cold water or the pure crystallization of acetone-cold water 2-3 time.The dihydromyricetin cellulose crystal is gone up separation and purification at C-18 reversed-phase column (normal pressure), is eluent with chloroform-methanol, collects the dibydro myricetrin flow point, and thin layer identifies that the back merges, and flings to partial solvent, gets purity and can reach single component dibydro myricetrin more than 98%.
Dibydro myricetrin and pharmaceutical preparation thereof have the effect of prevention and treatment senile dementia, and these pharmacological actions are confirmed by following pharmacodynamics test.
1, dibydro myricetrin causes the influence of mouse memory obstacle to Sodium Nitrite
Get 60 of mouse, press table 1 grouping at random.Each organized gastric infusion after 7 days, and except that normal group, all the other respectively organize subcutaneous injection Sodium Nitrite 120mg/kg immediately after training, each is organized in training last administration in back 24 hours, and with administration after carried out the diving tower experiment in 1 hour, latent period and errors number that the record animal is made mistakes the results are shown in Table 1.
Table 1, dibydro myricetrin cause influence (n=10, the X ± S) of mouse memory obstacle to Sodium Nitrite
△Compare with model group,
△P＜0.05,
△ △P＜0.01
The result shows that the large, medium and small dosage group of dibydro myricetrin causes the mouse memory obstacle to Sodium Nitrite and all improves significantly, and can obviously reduce the number of times that mouse is made mistakes, and prolongs the latent period that mouse is made mistakes.
2, dibydro myricetrin is to AlCl
3Cause the influence of mouse memory obstacle
Get 60 of mouse, press table 2 grouping at random.The 1st day to the 7th day, control group subcutaneous injection every day physiological saline, all the other respectively organize mouse subcutaneous injection AlCl
350mg/kg.The medication group is irritated 2 weeks of stomach successive administration respectively.Keep away dark test, the errors number that mouse enters the darkroom in the record 3min is remembered achievement with errors number and the test of wrong percentage behind the 24h.
Table 2, dibydro myricetrin are to AlCl
3Cause influence (n=10, the X ± S) of mouse memory obstacle
* compare * P＜0.05, * * P＜0.01 with normal group;
△Compare with model group,
△P＜0.05,
△ △P＜0.01
Illustrate that the dibydro myricetrin various dose is to AlCl
3Causing dysmnesia all has in various degree antagonism effect, and each treatment group and model group comparison error number of times have significant difference (P＜0.01), and the mistake incidence also has significant difference (P＜0.05).
3, dibydro myricetrin causes the influence of mouse memory obstacle to Scopolamine
Get 60 of mouse, press table 3 grouping at random.The 1st day to the 7th day, control group and model group were given distilled water, and all the other each groups are pressed table 3 administration.Once a day, continuous 7 days, behind the last administration 1h, normal group was given physiological saline 0.1ml/10g, and all the other each groups are given scopolamine hydrobromide 3mg/kg, carry out the diving tower experiment behind the 10min, test behind the 24h.The results are shown in Table 3.
Table 3 dibydro myricetrin causes influence (n=10, the X ± S) of mouse memory obstacle to Scopolamine
△Compare with model group,
△P＜0.05,
△ △P＜0.01
Scopolamine hydrobromide group mouse wrong times significantly increases than normal group, and the medication group has obviously reduced the errors number of mouse, illustrates that dibydro myricetrin has tangible antagonistic action (P＜0.01) to the mouse memory obstacle due to the scopolamine hydrobromide group.
4, dibydro myricetrin is to the influence of senile dementia model mice brain mitochondria superoxide-dismutase SOD activity, mda (MDA) content and brain coefficient.
Get 60 of mouse, be divided into normal control group and model group at random.Model group is given AlCl
3Solution begins to press in 70 days 400mg/kg/d and irritates stomach, uses 2000mg/LAlCl later on always
3Solution is drunk; The normal control group is irritated the distilled water of stomach equivalent.Model group is divided into 5 groups at random, presses shown in the table 1, gastric infusion 60 days, normal control group Model of Dementia group is irritated the distilled water with amount.Whole experiment is avoided contacting with aluminum products.Put to death mouse, in ice bath, take out cerebral tissue rapidly, and accurately take by weighing, measure SOD, MDA and calculating brain coefficient respectively.Experimental result sees Table 4.
Table 4, dibydro myricetrin are to senile dementia model mice brain SOD activity, MDA content
And the influence of brain coefficient (n=10, X ± S)
* compare * P＜0.05, * * P＜0.01 with normal group;
△Compare with model group,
△P＜0.05,
△ △P＜0.01
Model control group and normal control group compare, and brain SOD is active to be reduced, and MDA content increases, and the brain coefficient reduces (P＜0.05).Compare with model group, the high, medium and low dosage group of dibydro myricetrin SOD is active to raise, and MDA content reduces, and illustrates that dibydro myricetrin has tangible antioxygenation, improves free radical excess metabolism in vivo.In the dibydro myricetrin, low dose group group brain coefficient significantly increases (P＜0.05), high dose group difference more remarkable (P＜0.01).Thereby the effect of anti-encephalatrophy is described.
5, dibydro myricetrin is to the influence of senile dementia model acetyl choline content.
Get 60 of mouse, be divided into normal control group and model group at random.Model group is given AlCl
3Solution begins to press in 70 days 400mg/kg/d and irritates stomach, uses 2000mg/LAlCl later on always
3Solution is drunk; The normal control group is irritated the isometric distilled water of stomach.Model group is divided into 5 groups at random, presses shown in the table 5, gastric infusion 60 days, normal control group Model of Dementia group is irritated with isopyknic distilled water.Whole experiment is avoided contacting with aluminum products.The rat sacrificed by decapitation, open cranium rapidly and peel off cerebral tissue (removing little cerebral tissue), get rinsing in the part cerebral tissue physiological saline, remove blood, filter paper is wiped away dried, and the adding cold saline is put into the homogenate pipe and fully ground at ice bath, makes 10% brain homogenate, centrifugal, get supernatant colorimetric method for determining cerebral tissue enzyme acetylcholine content.Experimental result sees Table 5.
Table 5, dibydro myricetrin are to the influence of senile dementia model acetyl choline content (n=10, X ± S)
* compare * P＜0.05, * * P＜0.01 with normal group;
△Compare with model group,
△P＜0.05,
△ △P＜0.01
Each treatment group and model group compare, and acetyl choline content reduces, and significant difference (P＜0.01) is arranged.And each dosage group of dibydro myricetrin and piracetam do not have significant difference.6, the acute toxicity test of mouse
With gastric infusion in the maximum administration volume of the tolerant maximum administration concentration of animal (0.5g/ml), mouse (0.4ml/10g body weight) a day 1 time, observing continuously has non-toxic reaction and animal dead in 7 days.Recording the result is: all none death of animal in the mouse 7 days, under this dosage, do not observe obvious acute toxic reaction.Its mouse maximum dosage-feeding is 20g/kg body weight/d.
The present invention executes example by following experiment to be achieved (confirmation)
Embodiment 1, dibydro myricetrin preparation:
Medicinal material 1kg, measure refluxing extraction 2-3 time for 8 times with 50-80% ethanol (preferred 70% ethanol), the each extraction 1～3 hour with the activated carbon decolorizing of extracting solution 0.5% (w/v), filtered, filtrate is by among the D101 or AB-8 macroporous resin that anticipate, effluent liquid concentrates and reclaims ethanol to 500ml, places crystallization (4-10 ℃), and is centrifugal, precipitation gets dihydromyricetin cellulose crystal (content 96.7%) with the pure crystallization of ethanol-water 2-3 time.The dihydromyricetin cellulose crystal is gone up separation and purification at C-18 reversed-phase column (normal pressure), with chloroform-methanol is eluent, collects the dibydro myricetrin flow point, and thin layer identifies that the back merges, fling to partial solvent, purity can reach single component dibydro myricetrin (content 98.9%) more than 98%.
Embodiment 1 (capsule)
Dibydro myricetrin 100g, medical starch is an amount of, mixes, granulate, drying, whole grain, the capsule of packing into No. 1 is made 1000, promptly.Each 1, every day 3 times.
Embodiment 2 (tablet)
Dibydro myricetrin raw material 100g, medical starch is an amount of, and dextrin is an amount of, mixes, granulate, drying, whole grain, drying, the adding lubricant is an amount of, and compressing tablet is made 1000, promptly.Each 1, every day 3 times.
Embodiment 3 (pill)
Take by weighing the 30g Macrogol 4000, in water-bath, melt, add dibydro myricetrin raw material 10g, stir, in the impouring insulating pipe, regulate thermostat, soup is splashed under 80-90 ℃ in the whiteruss that cooled off, after dripping off, will blot paraffin oil on the pill impouring filter paper, make 1000, promptly.Each 10, every day 3 times.
Embodiment 4 (granule)
Dibydro myricetrin raw material 100g, Icing Sugar 400g mixes, and uses an amount of alcohol granulation, and dry, whole grain, packing are made 500 bags, promptly.Each 0.5 bag, every day 3 times.
Claims (10)
1, the novel method of extraction dibydro myricetrin is characterised in that in Vitaceae Ampelopsis Ampelopsis Michx plant Stem or leaf of Amur Ampelopsis (Ampelopsissinica (Miq.) W.T.Wang) cauline leaf and Ampelopsis grossedentata (Ampelopsis grossedetata (Hand-Mazz) W.T.wang) cauline leaf: medicinal material extracts one or many with aqueous ethanol, methanol solution, filtered while hot, united extraction liquid, add gac, filter, filtrate is crossed macroporous resin column, and effluent liquid concentrates, crystallization gets crude extract; Crude extract must the dihydromyricetin cellulose crystal with ethanol-cold water, methyl alcohol-cold water or acetone-cold water recrystallization 2-3 time.The dihydromyricetin cellulose crystal is gone up separation and purification at C-18 reversed-phase column (normal pressure), is eluent with chloroform-methanol, collects the dibydro myricetrin flow point, and thin layer identifies that the back merges, and flings to partial solvent, gets purity and can reach single component dibydro myricetrin more than 95%.
2,, it is characterized in that consumption when 50-80% aqueous ethanolic solution or methanol aqueous solution extract is heavy 5-50 times of medicinal material according to right 1 described method; Extraction time is 1h-3h;
3,, it is characterized in that the gac add-on is 0.01-3% (W/V) according to right 1 described method.
4,, it is characterized in that macroporous resin is mainly AB-8, D101, D201, LX-38, D3500, D4020, D941, HP-20, LX-28 type according to right 1 described method.Our preferred AB-8, D101 resin.
5, according to right 1 described method, it is characterized in that recrystallization temperature is 4-10 ℃, recrystallization solvent is 10-90% ethanol, methyl alcohol, acetone soln.
6,, it is characterized in that the dibydro myricetrin crystal purity reaches more than 95% according to right 1 described method.
7, a kind of pharmaceutical preparation is characterized in that containing dibydro myricetrin and one or more pharmaceutically acceptable pharmaceutical excipients of dose therapeutically effective, or can with the other medicines of dibydro myricetrin prescription.
8, pharmaceutical preparation according to claim 6, but it is characterized in that containing the pharmaceutical excipient of 1%-99% dibydro myricetrin and 99%-1% or the medicine of other prescription.
9, pharmaceutical preparation according to claim 6 is characterized in that said medicine is the formulation of oral preparations or parenterai administration.
10, the described preparation of claim 6 is used for prevention and treatment senile dementia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100665184A CN101475553A (en) | 2009-02-12 | 2009-02-12 | Preparation, medicinal preparation and use of dihydromyricetrin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100665184A CN101475553A (en) | 2009-02-12 | 2009-02-12 | Preparation, medicinal preparation and use of dihydromyricetrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101475553A true CN101475553A (en) | 2009-07-08 |
Family
ID=40836337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100665184A Pending CN101475553A (en) | 2009-02-12 | 2009-02-12 | Preparation, medicinal preparation and use of dihydromyricetrin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101475553A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106931A (en) * | 2010-12-30 | 2011-06-29 | 张家界茅岩莓有限公司 | Method for producing diverse extracts of berry tea |
| CN103251113A (en) * | 2013-04-29 | 2013-08-21 | 广东工业大学 | Preparation method of novel bacteriostatic agent by using dihydromyricetin collaborative organic acid as raw material |
| CN103772338A (en) * | 2014-01-10 | 2014-05-07 | 吉首大学 | Vacuum pulse type method of preparing dihydromyricetin |
| US20140220166A1 (en) * | 2011-10-12 | 2014-08-07 | University Industry Cooperation Group Of Kyung Hee University | Pharmaceutical composition containing extract of houttuynia cordata as active ingredient for preventing and treating dementia, parkinson's disease, or epilepsy |
| CN103833715B (en) * | 2014-03-04 | 2015-10-21 | 河南科技大学 | A kind of method of dibydro myricetrin in fermented extracted Maoyanmei tea |
| CN105712966A (en) * | 2016-01-22 | 2016-06-29 | 梁京 | Phenol tea acid and preparation method and application thereof |
| CN107365330A (en) * | 2017-07-10 | 2017-11-21 | 石家庄学院 | Dihydromyricetin two banks mono-sodium salt derivative and its preparation method and application |
| CN109305954A (en) * | 2018-11-21 | 2019-02-05 | 中南民族大学 | A method of isolating and purifying dihydromyricetin from vine tea |
| CN110051658A (en) * | 2019-03-28 | 2019-07-26 | 华南农业大学 | Application of the dihydromyricetin in the product of preparation prevention or treatment obesity |
| CN111437323A (en) * | 2020-04-30 | 2020-07-24 | 山东理工大学 | Application of vine tea extract in medicine for preventing and treating Alzheimer disease |
| CN111892566A (en) * | 2019-05-05 | 2020-11-06 | 首都医科大学 | Ampelopsis grossedentata water extract, preparation method thereof and application of water extract as acetylcholinesterase inhibitor |
-
2009
- 2009-02-12 CN CNA2009100665184A patent/CN101475553A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106931B (en) * | 2010-12-30 | 2013-03-20 | 张家界茅岩莓有限公司 | Method for producing diverse extracts of berry tea |
| CN102106931A (en) * | 2010-12-30 | 2011-06-29 | 张家界茅岩莓有限公司 | Method for producing diverse extracts of berry tea |
| US9861674B2 (en) * | 2011-10-12 | 2018-01-09 | University-Industry Cooperation Group Of Kyung Hee University | Pharmaceutical composition containing extract of houttuynia cordata as active ingredient for preventing and treating dementia, parkinson's disease, or epilepsy |
| US20140220166A1 (en) * | 2011-10-12 | 2014-08-07 | University Industry Cooperation Group Of Kyung Hee University | Pharmaceutical composition containing extract of houttuynia cordata as active ingredient for preventing and treating dementia, parkinson's disease, or epilepsy |
| CN103251113A (en) * | 2013-04-29 | 2013-08-21 | 广东工业大学 | Preparation method of novel bacteriostatic agent by using dihydromyricetin collaborative organic acid as raw material |
| CN103772338A (en) * | 2014-01-10 | 2014-05-07 | 吉首大学 | Vacuum pulse type method of preparing dihydromyricetin |
| CN103833715B (en) * | 2014-03-04 | 2015-10-21 | 河南科技大学 | A kind of method of dibydro myricetrin in fermented extracted Maoyanmei tea |
| CN105712966A (en) * | 2016-01-22 | 2016-06-29 | 梁京 | Phenol tea acid and preparation method and application thereof |
| CN105712966B (en) * | 2016-01-22 | 2018-06-12 | 梁京 | A kind of phenol boheic acid element and its preparation method and application |
| CN107365330A (en) * | 2017-07-10 | 2017-11-21 | 石家庄学院 | Dihydromyricetin two banks mono-sodium salt derivative and its preparation method and application |
| CN109305954A (en) * | 2018-11-21 | 2019-02-05 | 中南民族大学 | A method of isolating and purifying dihydromyricetin from vine tea |
| CN110051658A (en) * | 2019-03-28 | 2019-07-26 | 华南农业大学 | Application of the dihydromyricetin in the product of preparation prevention or treatment obesity |
| CN111892566A (en) * | 2019-05-05 | 2020-11-06 | 首都医科大学 | Ampelopsis grossedentata water extract, preparation method thereof and application of water extract as acetylcholinesterase inhibitor |
| CN111437323A (en) * | 2020-04-30 | 2020-07-24 | 山东理工大学 | Application of vine tea extract in medicine for preventing and treating Alzheimer disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101475553A (en) | Preparation, medicinal preparation and use of dihydromyricetrin | |
| TWI330087B (en) | The use of wenguanguo (xanthoceras sorbifolia) saponins for the manufacture of medicament for activating brain function, mehods for preparing saponins and medical compositions thereof | |
| CN101293038B (en) | Gallbladder leaves extract, preparing method, its preparation and uses | |
| WO2021017925A1 (en) | Application of radix pseudostellariae cyclic peptide b in improving memory and/or preventing and treating alzheimer's disease | |
| CN101747405A (en) | Berberine glycyrrhizic acid enantiomer salt and preparation method and usage thereof | |
| CN101843627B (en) | Application of dihydrophenanthrene glycoside compound in preparing medicines for preventing and curing cardiovascular and cerebrovascular diseases | |
| JP6735347B2 (en) | Composition for improving memory, which contains an extract of butterbur leaves | |
| CN101297823A (en) | Medicament for preventing and treating Alzheimer's disease | |
| CN1616381A (en) | Process for preparing Erigeron breviscapus active component | |
| CN101297900A (en) | Medicine new purpose of Ampelopsis Sinica stem leaf total flavones and single component myricetin | |
| JP2004518751A (en) | Method for producing Liangtoujian extract, pharmaceutical composition containing the extract and use thereof | |
| US20180169172A1 (en) | Compound and method for reducing appetite, fatigue and pain | |
| CN106822166B (en) | A kind of drug for preventing and treating diabetes and hyperlipidemia and its application in pharmacy | |
| CN101250175A (en) | Preparation of myricetin, medicinal preparation and new medical usage | |
| KR101384423B1 (en) | Medical composition comprising Perilla frutescens extract for preventing or treating brain neuronal disease | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN101559066B (en) | Use of beta-galactosides and composition in preparing medicine for myocardial ischemia | |
| CN103156923A (en) | Application of humulus lupulus effective parts applied to preparation of medicine for preventing and improving depression and clinical symptoms | |
| CN105566436A (en) | Tea seed flavonoid aglycone and tea sapogenin zinc coordination complex, method for preparing same and application of tea seed flavonoid aglycone and tea sapogenin zinc coordination complex | |
| CN106822338B (en) | Compound composition for reducing blood sugar and blood fat and preventing and/or treating diabetes and complications thereof and application thereof | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN109350632A (en) | A kind of Chinese medicine composition for antipyretic-antalgic | |
| WO2014133286A1 (en) | Composition containing extracts of artemisia iwayomogi and curcuma longa as active ingredients for preventing, inhibiting, or treating obesity-related diseases | |
| CN101822705A (en) | Total platycodin and application of monomer platycodin D in antialcoholic drugs | |
| CN101785816B (en) | Grass-leaved sweetflag extract, medicine composition with grass-leaved sweetflag extract, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090708 |